In the September 2007 issue of TCPR, we reviewed the very mixed literature on whether it makes sense to increase the dose of an antidepressant to achieve a response. We concluded that there is insufficient evidence, but that as long as you can avoid side effects, there is no compelling reason not to try dose escalation.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.